Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus

Oncogene volume 25, pages 3084–3092 (2006)Cite this article

Abstract

Aberrant activation of the Wnt signaling pathway has been reported during neoplastic progression in Barrett's esophagus (BE). However, mutations in APC and CTNNB1 genes were rarely observed. In this study, expression pattern of Wnt ligands, Frizzled receptors and APC, as well as the methylation status of the APC, SFRP1 and SFRP2 promoter genes were investigated in normal esophageal mucosa and in preneoplastic and neoplastic lesions of BE patients. Promoter methylation of APC was found in all BE samples and in 95% of esophageal adenocarcinomas (EAC). Full methylation of APC correlated with lack of expression. In EAC, nuclear translocation of β-catenin was observed regardless of the expression of APC. WNT2 expression was higher in dysplasia and EAC than in BE, with 20/26 (77%) of the EAC showing high expression of WNT2. SFRP1 methylation occurred in all BE samples and in 96% of EAC, while SFRP2 was methylated in 73% of the normal squamous esophageal mucosa samples. In conclusion, (1) alterations of key regulators of the Wnt signaling are frequent in the pathogenesis of BE; (2) the APC and SFRP1 genes are inactivated by promoter methylation in BE; (3) the WNT2 gene is upregulated along the progression from low-grade dysplasia to EAC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Baisse B, Bian YS, Benhattar J . (2000). Biotechniques 28: 856–858, 860, 862.

  • Benhattar J, Clement G . (2004). Methods Mol Biol 287: 181–193.

  • Bian YS, Osterheld MC, Bosman FT, Fontolliet C, Benhattar J . (2000). Am J Clin Pathol 114: 583–590.

  • Bian YS, Yan P, Osterheld MC, Fontolliet C, Benhattar J . (2001). Biotechniques 30: 66–72.

  • Bienz M, Clevers H . (2000). Cell 103: 311–320.

  • Blasband A, Schryver B, Papkoff J . (1992). Oncogene 7: 153–161.

  • Blot WJ, McLaughlin JK . (1999). Semin Oncol 26: 2–8.

  • Brabender J, Marjoram P, Salonga D, Metzger R, Schneider PM, Park JM et al. (2004). Oncogene 23: 4780–4788.

  • Bui TD, Zhang L, Rees MC, Bicknell R, Harris AL . (1997). Br J Cancer 75: 1131–1136.

  • Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P et al. (2004). Cancer Res 64: 883–888.

  • Clement G, Benhattar J . (2005). J Clin Pathol 58: 155–158.

  • Clement G, Bosman FT, Fontolliet C, Benhattar J . (2004). Cancer Res 64: 6867–6873.

  • Falk GW . (2002). Gastroenterology 122: 1569–1591.

  • Flejou JF . (2005). Gut 54: i6–i12.

  • Gonzalez MV, Artimez ML, Rodrigo L, Lopez-Larrea C, Menendez MJ, Alvarez V et al. (1997). J Clin Pathol 50: 212–217.

  • Guillou L, Coindre J, Gallagher G, Terrier P, Gebhard S, de Saint Aubain SN et al. (2001). Hum Pathol 32: 105–112.

  • He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N et al. (2005). Cancer Res 65: 743–748.

  • Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T, Truong T . (2002). Mol Pathol 55: 220–226.

  • Horii A, Nakatsuru S, Ichii S, Nagase H, Nakamura Y . (1993). Hum Mol Genet 2: 283–287.

  • Howng SL, Wu CH, Cheng TS, Sy WD, Lin PC, Wang C et al. (2002). Cancer Lett 183: 95–101.

  • Jenkins GJ, Doak SH, Parry JM, D'Souza FR, Griffiths AP, Baxter JN . (2002). Br J Surg 89: 824–837.

  • Katoh M . (2001a). Int J Mol Med 8: 657–660.

  • Katoh M . (2001b). Int J Oncol 19: 1003–1007.

  • Katoh M . (2003). Int J Mol Med 12: 811–816.

  • Kawano Y, Kypta R . (2003). J Cell Sci 116: 2627–2634.

  • Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, Carvalho M et al. (1998). Clin Cancer Res 4: 2195–2200.

  • Kobayashi K, Ouchida M, Tsuji T, Hanafusa H, Miyazaki M, Namba M et al. (2002). Gene 282: 151–158.

  • Koppert LB, van der Velden AW, van de Wetering M, Abbou M, van den Ouweland AM, Tilanus HW et al. (2004). Br J Cancer 90: 892–899.

  • Le Floch N, Rivat C, De WO, Bruyneel E, Mareel M, Dale T et al. (2005). FASEB J 19: 144–146.

  • Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J et al. (2004). Oncogene 23: 6672–6676.

  • Logan CY, Nusse R . (2004). Annu Rev Cell Dev Biol 20: 781–810.

  • McManus DT, Olaru A, Meltzer SJ . (2004). Cancer Res 64: 1561–1569.

  • Metzger R, Schneider PM, Warnecke-Eberz U, Brabender J, Holscher AH . (2004). Onkologie 27: 200–206.

  • Morin PJ . (1999). Bioessays 21: 1021–1030.

  • Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. (1997). Science 275: 1787–1790.

  • Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T . (1993). J Cancer Res Clin Oncol 119: 441–449.

  • Nusse R, Varmus HE . (1982). Cell 31: 99–109.

  • Osterheld MC, Bian YS, Bosman FT, Benhattar J, Fontolliet C . (2002). Am J Clin Pathol 117: 451–456.

  • Pham K, Milovanovic T, Barr RJ, Truong T, Holcombe RF . (2003). Mol Pathol 56: 280–285.

  • Polakis P . (1999). Curr Opin Genet Dev 9: 15–21.

  • Polakis P . (2000). Genes Dev 14: 1837–1851.

  • Rhee CS, Sen M, Lu D, Wu C, Leoni L, Rubin J et al. (2002). Oncogene 21: 6598–6605.

  • Ricken A, Lochhead P, Kontogiannea M, Farookhi R . (2002). Endocrinology 143: 2741–2749.

  • Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR . (1997). Br J Cancer 75: 258–263.

  • Saitoh T, Mine T, Katoh M . (2002). Int J Mol Med 9: 515–519.

  • Seery JP, Syrigos KN, Karayiannakis AJ, Valizadeh A, Pignatelli M . (1999). Acta Oncol 38: 945–948.

  • Shih IM, Yu J, He TC, Vogelstein B, Kinzler KW . (2000). Cancer Res 60: 1671–1676.

  • Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD et al. (2004). Nat Genet 36: 417–422.

  • Tsuchiya T, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z et al. (2000). Oncogene 19: 3642–3646.

  • Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB . (2003). Clin Cancer Res 9: 1291–1300.

  • Worm J, Christensen C, Gronbaek K, Tulchinsky E, Guldberg P . (2004). Oncogene 23: 5215–5226.

Download references

Acknowledgements

We thank Patricia Martin, Maude Muriset, Adeline Cottier and Tian Lu for skillful laboratory work. This study was supported by a grant from the Ligue Suisse contre le Cancer (Grant KLS-01327-02-2003).

Author information

Authors and Affiliations

  1. Institut de Pathologie, Centre Hospitalier Universitaire Vaudois, Lausanne, CH-1011, Switzerland

    G Clément, R Braunschweig, N Pasquier, F T Bosman & J Benhattar

Authors
  1. G Clément
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Braunschweig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Pasquier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F T Bosman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Benhattar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Benhattar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clément, G., Braunschweig, R., Pasquier, N. et al. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 25, 3084–3092 (2006). https://doi.org/10.1038/sj.onc.1209338

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209338

Keywords

This article is cited by

Search

Advanced search

Quick links